Vinpocetine - instructions for use, dose, side effects, contraindications

potato starch - 64.3 mg, lactose monohydrate (sugar milk) - 171.9 mg, silicon dioxide colloid (aerosil) - 1.7 mg, talc - 4.7 mg, magnesium stearate - 2.4 mg.

Description:

Tablets are white or white with a yellowish tint of color,flat-cylindrical shape with a risk and chamfer.

Pharmacotherapeutic group:Cerebral blood flow improver

ATX: & nbsp

N.06.B.X.18 Vinpocetine

Pharmacodynamics:

Vasodilating agent. Improves the metabolism of the brain, increasing the intake of glucose and oxygen by brain tissue. Increases the resistance of neurons to hypoxia; facilitates the transport of glucose to the brain,through the blood-brain barrier; translates the process of the decay of glucose into an energetically more economical, aerobic pathway; selectively blocks Ca²⁺ - dependent phosphodiesterase; increases the content of adenosine monophosphate (AMP), cyclic guanosine monophosphate (cGMP), ATP, norepinephrine, serotonin and the ratio of ATP / AMP in the brain tissues; has an antioxidant effect.

Reduces platelet aggregation and increased blood viscosity; increases the deforming ability of erythrocytes and blocks the utilization of adenosine by red blood cells; helps to increase the return of oxygen in the erythrocytes.

Increases cerebral blood flow; reduces the resistance of cerebral vessels without a significant change in the indices of the systemic circulation. Does not have the effect of "stealing" and enhances blood supply, especially in ischemic areas of the brain.

Pharmacokinetics:

Quickly absorbed. Time to reach the maximum concentration in blood plasma - 1 hour. Absorption occurs mainly in the proximal parts of the gastrointestinal tract. When passing through the wall of the intestine is not exposed to metabolism.The maximum concentration in tissues is noted 2-4 hours after ingestion. The connection with proteins - 66%, absolute bioavailability with ingestion - 7%, increases with the use of the drug after meals. Clearance 66.7 l / h. exceeds the plasma volume of the liver (50 l / h), which indicates an extrahepatic metabolism.

With repeated administration, the kinetics is linear. The half-life in humans is 4.83 ± 1.29 hours. It is excreted by the kidneys and through the intestine in a ratio of 3: 2. Penetrates through the placental barrier.

Indications:

- neurological and psychiatric symptoms in various forms of cerebral circulatory insufficiency (including the reducing step ischemic or hemorrhagic stroke, the effects of stroke, transient ischemic attack, vascular dementia; vertebrobasilar insufficiency, cerebral atherosclerosis, traumatic and hypertensive encephalopathy);

- chronic vascular diseases of the choroid and retina (due to arteriosclerosis, angiospasm, thrombosis); degenerative changes in the macula caused by atherosclerosis or angiospasm; secondary glaucoma (due to vascular obturation);

- age-related vascular or toxic (medicamentous) hearing disorders, Meniere's disease, idiopathic tinnitus, dizziness of labyrinthine origin;

- vasovegetative manifestations of climacteric syndrome.

Contraindications:

- acute phase of hemorrhagic stroke, ischemic heart disease, severe arrhythmias.

- hypersensitivity to any of the components of the drug.

- pregnancy (possibly placental bleeding and spontaneous abortion, probably as a result of increased placental blood supply).

- lactation period (with the drug should stop breastfeeding).

- children under 18 years (due to insufficient data).

- tablets contain lactose, therefore, the drug should not be taken by patients with rare hereditary diseases, such as galactose intolerance, lactase deficiency or glucose-galactose malabsorption.

Dosing and Administration:

Inside to 5 mg (1 tab.) After eating. The drug is applied 3 times a day. The initial daily dose is 15 mg. The maximum daily dose is 30 mg. Duration of treatment to 3 months. Possible repeated courses 2-3 times a year.

In diseases of the kidneys or liver, the drug is prescribed in the usual dose.

Before cancellation, the dosage of the drug should be gradually reduced.

Side effects:

From the cardiovascular system: change in ECG (depression ST, lengthening the interval QT), tachycardia, extrasystole, lability of blood pressure, sensation of hot flashes.

From the central nervous system: sleep disturbances (insomnia, increased drowsiness), dizziness, headache, general weakness, increased sweating. On the part of the digestive system: dry mouth, nausea, heartburn.

Skin allergic reactions.

Overdose:

Symptoms: increased severity of side effects.

Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.

Interaction:

Interactions are not observed with simultaneous use with β-blockers (chloranolol, pindolol), clopamid, glibenclamide, digoxin, acenocoumarol and hydrochlorothiazide, imipramine.

The simultaneous use of vinpocetine and methyldopa sometimes caused some strengthening of the hypotensive effect, so this treatment requires regular monitoring of blood pressure.

Increases the risk of hemorrhagic complications against heparin therapy.

Despite the lack of data confirming the possibility of interaction, it is recommended to exercise caution when concurrently administering with the drugs central, antiarrhythmic and anticoagulant action.

Special instructions:

Presence of the syndrome of the prolonged interval QT and taking medications that elongate the interval QT, requires periodic ECG monitoring.

Effect on the ability to drive transp. cf. and fur:

Data on the effect of vinpocetine on the ability to drive a car and perform work that requires speed of psychomotor reactions is not.

Form release / dosage:Tablets of 5 mg.

Packaging:

10 tablets per contour cell pack. 1, 2, 3, 4 or 5 contour mesh packages with instructions for use in a pack of cardboard.

Storage conditions:

In a dry, protected from light place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:5 years. Do not use after the date indicated on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N003245 / 01

Date of registration:30.06.2009

Expiration Date:Unlimited

The owner of the registration certificate:ALSI Pharma, ZAO ALSI Pharma, ZAO Russia

Manufacturer: & nbsp

ALSI Pharma, ZAO Russia

Information update date: & nbsp19.02.2017

Illustrated instructions

Instructions

Vinpocetine (Vinpocetine)